|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Follicular thyroid carcinoma (FTC) frequently harbors the PAX8/PPARgamma fusion gene (PPFP); however, its oncogenic role and mechanism(s) of action remain undefined.
|
15077183 |
2004 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A proportion of FTC has been found to be associated with a chromosomal translocation, t (2, 3)(q13;p25), which fuses the thyroid-specific transcription factor paired box-8 with the peroxisome proliferator-activated receptor-gamma nuclear receptor, a ubiquitously expressed transcription factor.
|
16946003 |
2007 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A recent study of follicular thyroid carcinomas reported a novel chromosomal translocation, t(2;3)(q13;p25), that fused the thyroid-specific transcription factor PAX8 with a nuclear receptor, peroxisome proliferator-activated receptor gamma (PPAR gamma).
|
12519876 |
2003 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A subset of follicular thyroid carcinomas contains a balanced translocation, t(2;3)(q13;p25), that results in fusion of the paired box gene 8 (PAX8) and peroxisome proliferator-activated receptor gamma (PPARG) genes with concomitant expression of a PAX8-PPARgamma fusion protein, PPFP.
|
16609007 |
2006 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Approximately 35% of follicular thyroid carcinomas and a small fraction of follicular adenomas are associated with a t(2;3)(q13;p25) chromosomal translocation that fuses paired box gene 8 (PAX8) with the peroxisome proliferator-activated receptor-gamma gene (PPARG), resulting in expression of a PAX8-PPARgamma fusion protein, PPFP.
|
19797117 |
2009 |
|
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As PAX8/PPARG and RET/PTC rearrangements have been detected in follicular thyroid carcinomas (FTCs) and papillary thyroid carcinomas (PTCs), their detection in FNA smears could improve the FNA diagnosis.
|
23025542 |
2012 |
|
Follicular thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Both FTC and FA, which did not harbor RAS, phosphoinositide-3-kinase, or PAX/peroxisome proliferator activated receptor-γ mutations, express various proteins in common and others that are more distinctly expressed in FTC rather than in FA or normal thyroid tissue.
|
21983636 |
2011 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection of either the PAX8-PPARG translocation or the 3p25 aneusomy in FTC indicates that these are independent genetic events.
|
19963130 |
2010 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we aimed to investigate the clinicopathological aspects of a large series of follicular thyroid carcinomas (FTCs) in paediatric patients and to analyse the point mutations in codons 12, 13 and 61 of NRAS, HRAS and KRAS genes and the rearrangements of PAX8-PPARG.
|
28621837 |
2017 |
|
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrate for the first time the presence of PAX8-PPARγ in PDs and FTUMPs, whereas in FTCs and PTCs the prevalence of PAX8-PPARγ is lower than previously reported.
|
23738683 |
2013 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we examined PAX8-PPARγ rearrangement in 24 FTC samples from Japanese patients by reverse transcribed-polymerase chain reaction (RT-PCR) using two upstream PAX8 primers located in exons 7 and 8 and a downstream primer in exon 1 of PPARγ.
|
25708358 |
2015 |
|
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Later, a fusion of the genes PAX8 and PPARG resulting from this translocation was frequently observed in follicular carcinomas and considered as a marker of follicular thyroid cancer.
|
21763631 |
2011 |
|
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in RAS or PAX8/PPARG were exclusive to FTC and fvPTC.
|
29108474 |
2018 |
|
Follicular thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mutations were detected in 2/5 FTC (PAX8/PPARγ and NRAS) and 3/6 FVPTC cases (PAX8/PPARγ).
|
26649796 |
2016 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Non-overlapping genetic alterations, including BRAF and RAS point mutations, and RET/PTC and PAX8/PPARγ rearrangements, are found in more than 70% of papillary and follicular thyroid carcinomas.
|
21739166 |
2011 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our experiments demonstrate the suppression of NORE1A, a known Ras effector, in PAX8-PPARgamma carrying FTCs.
|
16352687 |
2006 |
|
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, among 20 PAX8/PPARγ-positive tumors that were surgically excised, 17 (85%) were PTC and 3 (15%) were FTC.
|
24798894 |
2014 |
|
Follicular thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PAX8-PPARgamma fusion gene expression was found in 25% (six of 24) of follicular thyroid carcinomas (FTCs) and in 17% (six of 36) of follicular thyroid adenomas, but in none of the 10 normal tissues, 28 nodular hyperplasias, 38 papillary thyroid carcinomas (PTCs) and 11 poorly differentiated thyroid carcinomas (PDTCs).
|
15238980 |
2004 |
|
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PAX8/PPARG fusion was found in I-EFVPTCs and FTC.
|
31671409 |
2019 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RAS mutations and PAX8/PPARγ rearrangements in 56 FTAs and 35 FTCs were analyzed.
|
25999051 |
2015 |
|
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, a translocation t(2; 3)(q13;p25), involving the fusion of PAX8 and peroxisome proliferator-activated receptor gamma (PPAR gamma) was suggested to arise only in follicular thyroid carcinomas.
|
12970322 |
2003 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Substantial improvement in the understanding of the oncogenic pathways in thyroid cancer has led to identification of specific molecular alterations, including mutations of BRAF and RET in papillary thyroid cancer, mutation of RAS and rearrangement of PPARG in follicular thyroid cancer, mutation of RET in medullary thyroid cancer, and mutations of TP53 and in the phosphatidylinositol 3'-kinase (PI3K)/AKT1 pathway in anaplastic thyroid cancer.
|
27618325 |
2017 |
|
Follicular thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surprisingly, several PPARgamma target genes were up-regulated in PAX8-PPARgamma-positive FTCs such as angiopoietin-like 4 and aquaporin 7.
|
15972966 |
2005 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The activating TSHR mutation could promote in vivo FTC development in PAX8-PPARgamma-positive thyrocytes under poor blood supply with deprivation of growth factors but restraint the tumor growth when growth factors are supplied.
|
20427420 |
2010 |
|
Follicular thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of PAX8-PPARgamma rearrangement was similar in FVPTCs (37.5%), FTCs (45.5%), and FTAs (33.3%).
|
16219715 |
2006 |